Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). Meeting Abstract

cited authors

  • Jain, Rohit K.; Swami, Umang; Bilen, Mehmet Asim; Boucher, Kenneth M.; Brown, Jacqueline T.; Chahoud, Jad; Gupta, Sumati; Agarwal, Neeraj; Sonpavde, Guru P.; Maughan, Benjamin L.

Publication Date

  • February 1, 2024

webpage

published in

category

keywords

  • 1
  • 130-540-543-4790
  • 171
  • 2
  • 242
  • 261-566-9263
  • 283-183-138-11076
  • 298-145-222-184-1022-9124
  • 3
  • 38092-20072
  • 38092-25535
  • 38092-29187
  • 4
  • 6
  • 613-135-2370-7650-2700
  • 613-7657-304
  • 62

start page

  • 539

end page

  • 539

volume

  • 42

issue

  • 4_SUPPL